Talnetant

Talnetant
(IUPAC) ime
	3-hydroxy-2-phenyl-N-(1-phenylpropyl)quinoline-4-carboxamide
Klinički podaci
Identifikatori
CAS broj	174636-32-9
ATC kod	nije dodeljen
PubChem	133090
Hemijski podaci
Formula	C25H22N2O2
Mol. masa	382.454 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C25H22N2O2/c1-2-20(17-11-5-3-6-12-17)27-25(29)22-19-15-9-10-16-21(19)26-23(24(22)28)18-13-7-4-8-14-18/h3-16,20,28H,2H2,1H3,(H,27,29) ; Key: BIAVGWDGIJKWRM-UHFFFAOYSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status

Talnetant (SB-223,412) je antagonist neurokininskog 3 receptora koji je razvio GlaksoSmitKlajn. Talnetant se ispituje za nekoliko različitih funkcija, primarna od kojih je upalna bolest creva. Druge indikacija je potencijalna antipsihotička primena u lečenju šizofrenije.^[3]^[4]^[5]

Vidi još uredi

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Evangelista S. Talnetant GlaxoSmithKline. Current Opinion on Investigational Drugs. 2005 Jul;6(7):717-21. PMID 16044668
↑ Houghton LA, Cremonini F, Camilleri M, Busciglio I, Fell C, Cox V, Alpers DH, Dewit OE, Dukes GE, Gray E, Lea R, Zinsmeister AR, Whorwell PJ. Effect of the NK(3) receptor antagonist, talnetant, on rectal sensory function and compliance in healthy humans. Neurogastroenterology and Motility. 2007 Sep;19(9):732-43. PMID 17727393
↑ Dawson LA, Cato KJ, Scott C, Watson JM, Wood MD, Foxton R, de la Flor R, Jones GA, Kew JN, Cluderay JE, Southam E, Murkitt GS, Gartlon J, Pemberton DJ, Jones DN, Davies CH, Hagan J. In Vitro and In Vivo Characterization of the Non-peptide NK(3) Receptor Antagonist SB-223412 (Talnetant): Potential Therapeutic Utility in the Treatment of Schizophrenia. Neuropsychopharmacology. 2008 Jun;33(7):1642-52. PMID 17728699

	Portal Medicina
	Portal Hemija